flutamide
TRANSCRIPT
![Page 1: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/1.jpg)
Prepare by
The pharmacist Ayia Nazum Kamal
![Page 2: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/2.jpg)
•Capsules:Capsules: 125 mg ,250mg
![Page 3: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/3.jpg)
Flutamide is nonsteroidal antiandrogen )anti-Flutamide is nonsteroidal antiandrogen )anti-) testosterone) testosterone inhibits androgen uptake or inhibits nuclear inhibits androgen uptake or inhibits nuclear binding of androgen in target tissues or binding of androgen in target tissues or.both.both
![Page 4: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/4.jpg)
The t1/2 is about 6 h )active.)metabolite
drug is excreted primarily in theurine with 4.2% excreted in feces
Elimination
Flutamide is rapidly and extensivelymetabolized to at least 6 metabolites . The active metabolite ishydroxyflutamide.
Metabolism
parent drug:94% to 96%Active metabolite:92% to 94%
proteinbinding
Oral: rapid and complete Absorption
![Page 5: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/5.jpg)
-1 Metastatic prostate cancer, combinationtherapy with a luteinizing hormone- releasing hormone )LHRH( analog )eg,.)goserelin, leuprolide-2Treatment of hirsutism in women
-3 Juvenile Nasopharyngeal Angiofibroma flutamide was reported to reduce stage I and.II tumors to 44%
![Page 6: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/6.jpg)
Prostate carcinoma:* 250mg 3 times daily )for a total daily dose of 750)mg
Female hirsutism )unlabeled*use(:250mg daily
![Page 7: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/7.jpg)
-1-1 hypersensivity to flutamide or any.. component of the formulation
_2_2..severe hepatic function impairment
-3-3pregnancy..
![Page 8: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/8.jpg)
GIGI Low potential for nausea and vomiting; diarrhea; hepatocellular necrosis;cholestatic jaundice; elevated LFTsEndocrineEndocrineHot flashes, gynecomastia
GenitourinaryGenitourinary Impotence; reduced sperm countCNSCNSDecreased libido
![Page 9: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/9.jpg)
* cardiac disease)oedema reported(. * hepatic impairment, also liver function tests, monthly for first 4 months, periodically thereafter and at the first sign or symptom ofliver disorder )e.g . pruritus, dark urine, persistent anorexia, jaundice, abdominalpain, unexplained influenza-like symptoms)
![Page 10: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/10.jpg)
Drug InteractionsDrug Interactions Prothrombin time may increase when flutamide therapy is initiated in patients.stabilized on chronic warfarin therapyLaboratory Test InteractionsLaboratory Test Interactions Elevated AST, ALT, bilirubin, BUN, andserum creatinine
![Page 11: Flutamide](https://reader036.vdocument.in/reader036/viewer/2022081404/559580661a28abce318b4655/html5/thumbnails/11.jpg)
The urine was noted to change to an*The urine was noted to change to an*amber or yellowamber or yellow--green appearancegreen appearance Photosensitization may occurPhotosensitization may occur* *
Flutamide and LHRH*Flutamide and LHRH*-- agonists should be agonists should beadministered concomitantlyadministered concomitantly